Search Results

You are looking at 1 - 10 of 552 items :

Clear All

hepatocellular carcinoma correlates with beta-catenin, Ki-67 index, and patient survival. Hepatology 2003; 38: 470-480 4. JUN CUI, BAO-WEI DONG, PING LIANG, XIAO-LING YU, DE-JIANG YU: Effect of c-myc, Ki-67, MMP-2 and VEGF expression on prognosis of hepatocellular carcinomapatients undergoing tumor resection, World J Gastroenterol 2004;10(10):1533-1536 5. D’ERRICO A, GRIGIONI WF, FIORENTINO M, BACCARINI P, GRAZI GL, MANCINI AM: Overexpression of p53 protein and Ki67 proliferative index in hepatocellular carcinoma: an immuno-histochemical study on 109 Italian patients. Pathol

Srivastava, Analysis of the immunoexpression of Ki-67 and Bcl-2 in the pericoronal tissues of impacted teeth, dentigeous cysts and gingiva using software image analysis, Dent Res J (Isfahan), 2013; 10:31-37. 6. Ozveren A, Tuskan C, Yaltirik M, Et all. Expresion or the tumor suppresor gene p53 in odontogenic cyst. Turk J Med Sci, 2003; 33:243-247. 7. Maryam Seyedmajidi, Shima Nafarzadeh, Sepideh Siadati, Shahryar Shafaee, Ali Bijani, Nazanin Kehmiri, p53 and PCNA expressin in Keratocystic odontogenic tumors compared with Selected Odontogenic Cysts, IJMCM, 2013, Vol 2, No 4

References Abele , M.C., Valente, G., Kerim, S., Navone, R., Onesti, P., Chiusa, L., Resegotti, L., and Palestro, G. ( 1997 ). Significance of cell proliferation index in assessing histological prognostic categories in Hodgkin's disease. An immunohistochemical study with Ki67 and MIB-1 monoclonal antibodies. Haematologica 82 , 281 –285. Endl , E. and Gerdes, J. ( 2000 ). The Ki-67 protein: fascinating forms and an unknown function. Exp. Cell Res. 257 , 231 –237. Fonatsch , C., Duchrow, M., Rieder, H., Schluter, C., and Gerdes, J. ( 1991 ). Assignment of the

Roentgenol 2007; 188: 1622-35. 9. Padhani AR, Liu G, Koh DM, Chenevert TL, Thoeny HC, Takahara T, et al. Diffusion-weighted magnetic resonance imaging as a cancer biomarker: consensus and recommendations. Neoplasia 2009; 11: 102-25. 10. Scholzen T, Gerdes J. The Ki-67 protein: from the known and the unknown. J Cell Physiol 2000; 182: 311-22. 11. Raĭkhlin NT, Bukaeva IA, Smirnova EA, Gurevich LE, Delektorskaia VV, Polotskiĭ BE, et al. Significance of the expression of nucleolar argyrophilic proteins and antigen Ki-67 in the evaluation of cell proliferative

[1] Al-Sader M.H., Doyle E., Kay E.W., Bennett M., Walsh C.B., Curran B., Milburn C. & Leader M. 1996. Proliferation indexes — a comparison between cutaneous basal and squamous cell carcinomas. J. Clin. Pathol. 49: 549–551. [2] Barrett T.L., Smith K.J., Hodge J.J., Butler R., Hall F.W. & Skelton H.G. 1997. Immunohistochemical nuclear staining for p53, PCNA, and Ki-67 in different histologic variants of basal cell carcinoma. J. Am. Acad. Dermatol. 37: 430–437. [3] Bartoš V

References 1. Von Eisenhart-Rothe R, Toepfer A, Salzmann M, Schauwecker J, Gollwitzer H, Rechl H. Primary malignant bone tumors. Orthopade. 2011 Dec; 40(12):1121-42. 2. Majid C, Keith H, Lee J. Primary malignant tumours of the bone. Surgery. 2009 February; 27(2):80-85. 3. Bruno S, Darzynkiewicz Z. Cell cycle dependent expression and stability of the nuclear protein detected by Ki-67 antibody in HL-60 cells. Cell Proliferation. 1992 January; 25(1):31–40. 4. Hernández-Rodríguez NA, Correa E, Sotelo R, Contreras-Paredes A, Gomez-Ruiz C, Green L, Mohar A et al. Ki-67

References 1. Agoff S.N., Lin P., Morihara J., Mao C., Kiviat N.B., Koutsky L.A.: p16INK4a expression correlates with degree of cervical neoplasia: A comparison with Ki-67 expression and detection of high-risk HPV types. Mod Pathol 2003, 16 , 665-673. 2. Barnard N.J., Hall P.A., Lemoine N.R., Kadar N.: Proliferative index in breast carcinoma determined in situ by Ki67 immunostaining and its relationship to clinical and pathological variables. J Pathol 1987, 152 , 287-295. 3. Beaumont P.R., O’Brien J.B., Allen H.L., Tucker J.A.: Mast cell sarcoma of the larynx

markers, has been associated with disease progression 4 or poor survival in prostate cancer 5 , but up to now its prognostic value has not been clarified because of controversial results 6 ; 7 , 8 . However, Epstein et al. 9 have recently suggested using neuroendocrine markers to better characterize and classify NED in prostate cancer. They also outlined Ki67 ranges in those tumors, which usually have a high proliferative index. 4 , 9 - 13 Ki67 is a well-known marker in oncology for defining tumor proliferation. Expression of Ki67 detection by immunohistochemistry

Introduction p16/Ki-67 dual immunocytochemical staining (DS) is considered easy to interpret if evaluators are properly trained. However, there is no consensus on what constitutes proper training. Authors have used different training approaches in studies investigating inter-observer reproducibility and accuracy of DS. 1 , 2 , 3 , 4 , 5 , 6 Most training protocols described in these studies consisted of initial and additional training. The initial training was provided by the manufacturer, however, it was not exactly the same in all cases except that it was

Introduction BC is a heterogeneous disease composed of different molecular intrinsic subtypes, each with distinctive and prognostic behaviors and responses to therapy [ 1 ], [ 2 ], [ 3 ], [ 4 ], [ 5 ]. An approximation of gene expression array results is possible using formalin-fixed paraffin-embedded material. In the daily oncological routine immunohistochemical parameters such as estrogen receptor (ER), progesterone receptor (PgR), human epidermal growth factor receptor 2 (HER2) and the proliferation-marker Ki67 are used as surrogate markers to define different